<DOC>
	<DOCNO>NCT01330303</DOCNO>
	<brief_summary>It open-label , randomize , laboratory-blind , crossover study 02 treatment , 02 sequence , 02 period , volunteer receive , period , test formulation reference formulation , fed condition .</brief_summary>
	<brief_title>SECOTEX® ( Tamsulosin Hydrochloride ) Bioequivalence Study Brazil - Fed Admin</brief_title>
	<detailed_description>It open-label , randomize , laboratory-blind , crossover study 02 treatment , 02 sequence , 02 period , volunteer receive , period , test formulation reference formulation , fed condition . The treatment 's sequence attribute volunteer study period determine randomization list , generate PROC PLAN SAS version 9.1.3 system . The formulation administer single oral dose follow blood collection , least , 3 5 half-lives . The treatment 's period may obey minimum interval 7 half life ( period drug 's whole elimination organism ) .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>EXCLUSION CRITERIA : The volunteer know hypersensitivity study drug ( tamsulosin hydrochloride ) compound chemically relate ; History presence hepatic gastrointestinal illness , condition interferes drug 's absorption , distribution , excretion metabolism ; History hepatic , renal , pulmonary , gastrointestinal , epileptic , hematologic psychiatric illness ; hypo hypertension etiologic need pharmacologic treatment ; history myocardial infarction , angina and/or heart insufficiency ; Nonrecommended electrocardiographic finding , accord investigator criterion ; The result laboratory exams value consider normal accord protocol 's rule , unless consider clinically irrelevant investigator ; Volunteer smoker ; The volunteer ingest 5 cup coffee tea day ; Has history alcohol drug abuse ; History serious adverse reaction hypersensitivity drug ; Use regular drug within 02 week precede study 's initiation treatment within 03 previous month , precede study 's initiation , drug present toxic , volunteer consume inductive drug and/or enzymatic inhibitor ( CYP450 hepatic ) , within 04 week precede study 's initiation ; Volunteer hospitalize reason within 08 week begin study 's first period treatment post study assessment date ; Participation experimental study ingestion experimental drug within 06 previous month ; Volunteer consume alcohol 48 hour prior admission study consume food beverage contain grapefruit 07 day previous study period . INCLUSION CRITERIA : Male ; Age 18 50 year ; Body mass index ≥ 19 ≤28,5 ; Good health condition without significant illness , judgment legally qualify professional , accord rule define Protocol , accord follow evaluation : clinical history , pressure pulse measure , physical psychological exam , ECG , additional laboratory exam ; Capable understand study 's nature aim , include risk adverse effect intention cooperate researcher act compliance requirement whole assay ; confirm Informed Consent 's signature .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>tamsulosin hydrochloride</keyword>
	<keyword>Fed administration</keyword>
</DOC>